Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma

NCT00503763 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-04-16

No results posted yet for this study

Summary

The aim of the study is to evaluate the effect of statin administration on the course of progressive Smoldering Multiple Myeloma.

Conditions

  • Smoldering Multiple Myeloma

Interventions

DRUG

Simvastatin

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Michael Lishner, MD · Meir Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-03-31
Completion
2009-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503763 on ClinicalTrials.gov